This paper describes development and evaluation of an inhalable dry-powder formulation containing peptide YY3–36 [PYY(3–36)], which has shown efficacy in appetite suppression when dosed by injection. The systemic pharmacokinetics of PYY3-36 were evaluated when delivered by intraperitoneal and subcutaneous injection and inhalation before selecting doses for an appetite-suppression pharmacodynamic study. The resulting pharmacokinetic data proved valuable in pharmacodynamic dose selection for inhalation delivery of the peptide. In addition, engineered PYY(3–36):Dextran T10 particles delivered to the respiratory tract show promise as a noninvasive therapeutic for appetite suppression.
Please note that Lonza has updated its Privacy Policy. By visiting our website or using services provided by Lonza, you are accepting the practices described in the Privacy Policy.
We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. Please read our updated Cookies Policy for information about which cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.
By clicking "I Agree", you confirm that you are above the age of 16, that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policies.